PK Study of Gefurulimab SC in Healthy Chinese Adult Participants
Study Identifier:
D6780C00003
ClinicalTrials.gov Identifier:
EudraCT Identifier:
N/A
Sponsor:
Alexion Pharmaceuticals, Inc.
Study Contact Information:
N/A
Study Complete
Study Details
Medical Condition
- Other
Study Drug
- Drug: gefurulimab
Date
Oct 2024 - Mar 2025
Phase 1
Phase 2
Phase 3
Phase 4
N/A
Patient Requirements
Sex: Female & Male
Age: 18 - 45 Years
Requirements Information
Sex
Female & Male
Age
18 - 45 Years
Study Details
Medical Condition
- Other
Study Drug
- Drug: gefurulimab
Date
Oct 2024 - Mar 2025
Phase 1
Phase 2
Phase 3
Phase 4
N/A
Patient Requirements
Sex: Female & Male
Age: 18 - 45 Years years
Requirements Information
Protocol Summary
The primary objective of this study is to characterize the PK properties of a single dose of gefurulimab in healthy Chinese participants.
Trial Locations
Location
Status
Location
Research Site
Shanghai, China, 201107
Status
N/A